Targets amide local anesthetic pathways to control symptoms and support evidence-based outpatient management.
Medications Starting With "L" (106)
“Can I Take These Together?” Build Your Conflict-Free Daily Schedule
Toggle your prescriptions and supplements below to see stomach mineral absorption blocks, CYP450 conflicts, and your exact 24-hour clock:
Take 30–60 min before coffee/breakfast; keep 4 hours away from Iron, Calcium & Magnesium.
Alternate-day morning dosing with 200 mg Vitamin C avoids the 24h hepcidin block and protects Levothyroxine.
Avoid potassium chloride salt substitutes or high-dose potassium supplements (hyperkalemia >5.2 mEq/L risk).
Fat-soluble D3, K2 (MK-7), Omega-3 rTG, and CoQ10 Ubiquinol absorb 32%–50% better with dietary fat.
Taking Extended-Release (ER) mid-dinner cuts GI nausea/diarrhea by >60%. Check Vitamin B12 + MMA yearly.
Pairs cleanly with dinner alongside CoQ10 Ubiquinol (100–200 mg) to support muscle mitochondrial ATP.
Safely separated 15 hours from morning Levothyroxine; glycine + Mg2+ support GABAergic deep sleep.
Never pay a $45–$68 retail pharmacy walk-in markup for pennies-per-pill generics:
Medications Starting With "L" (106)
Targets amide local anesthetic pathways to control symptoms and support evidence-based outpatient management.
Lidocaine Patch 5%
Targets amide local anesthetic pathways to control symptoms and support evidence-based outpatient management.
Targets amide local anesthetic pathways to control symptoms and support evidence-based outpatient management.
Targets amide local anesthetic pathways to control symptoms and support evidence-based outpatient management.
Targets amide local anesthetic pathways to control symptoms and support evidence-based outpatient management.
Targets amide local anesthetic pathways to control symptoms and support evidence-based outpatient management.
Targets amide local anesthetic pathways to control symptoms and support evidence-based outpatient management.
Lifitegrast
Targets lymphocyte function-associated antigen-1 antagonist pathways to control symptoms and support evidence-based outpatient management.
Lincomycin Hydrochloride
Targets fda prescription monograph pathways to control symptoms and support evidence-based outpatient management.
Linerixibat
Targets ileal bile acid transporter inhibitor pathways to control symptoms and support evidence-based outpatient management.
Linezolid
Inhibits microbial cell-wall, ribosomal, or viral polymerase replication to clear targeted infections.
Lisdexamfetamine Dimesylate
Targets central nervous system stimulant pathways to control symptoms and support evidence-based outpatient management.
Targets mood stabilizer pathways to control symptoms and support evidence-based outpatient management.
Lithium Carbonate
Targets mood stabilizer pathways to control symptoms and support evidence-based outpatient management.
Inhibits microbial cell-wall, ribosomal, or viral polymerase replication to clear targeted infections.
Lofexidine Hydrochloride
Targets fda prescription monograph pathways to control symptoms and support evidence-based outpatient management.
Lolium Perenne
Targets standardized pollen allergenic extract pathways to control symptoms and support evidence-based outpatient management.
Lomitapide Mesylate
Targets microsomal triglyceride transfer protein inhibitor pathways to control symptoms and support evidence-based outpatient management.
Lomustine
Targets alkylating drug pathways to control symptoms and support evidence-based outpatient management.
Lonafarnib
Targets farnesyltransferase inhibitor pathways to control symptoms and support evidence-based outpatient management.
Loperamide Hydrochloride
Targets opioid agonist pathways to control symptoms and support evidence-based outpatient management.
Loratadine
Targets allergies agent pathways to control symptoms and support evidence-based outpatient management.
Loratadine Oral
Targets allergies agent pathways to control symptoms and support evidence-based outpatient management.
Lorazepam
Targets benzodiazepine pathways to control symptoms and support evidence-based outpatient management.
Lorlatinib
Targets kinase inhibitor pathways to control symptoms and support evidence-based outpatient management.
Loteprednol Etabonate
Targets corticosteroid pathways to control symptoms and support evidence-based outpatient management.
Lotilaner Ophthalmic Solution
Targets ectoparasiticide pathways to control symptoms and support evidence-based outpatient management.
Lovastatin
Lowers atherogenic LDL-C and ApoB particles within 4–6 weeks to reduce arterial plaque progression.
Loxapine
Targets mental health agent pathways to control symptoms and support evidence-based outpatient management.
Lubiprostone
Targets chloride channel activator pathways to control symptoms and support evidence-based outpatient management.
Lumasiran
Targets fda prescription monograph pathways to control symptoms and support evidence-based outpatient management.
Lurasidone Hydrochloride
Targets atypical antipsychotic pathways to control symptoms and support evidence-based outpatient management.
Lutetium Lu 177 Vipivotide Tetraxetan
Targets radioligand therapeutic agent pathways to control symptoms and support evidence-based outpatient management.
Pair Your Prescription Guide With Diagnostic Cutoffs & Nutrient Depletion Rules
Diagnostic Lab Cutoffs & First-Line Protocols
See exact ACC/AHA blood pressure stages, ADA HbA1c thresholds, and step-up treatment ladders across 40 specialty hubs.
Drug-Induced Nutrient Depletions & Label Math
Check when statins, Metformin, or PPIs deplete CoQ10, Vitamin B12, or Magnesium—and how to decode elemental supplement labels.
GreatDoc™ Score & Zero-Wall Insurance Check
Find board-certified endocrinologists, cardiologists, and internists verified by CMS Medicare Part B volume and accepted insurance plans.
How does dotMD.com verify FDA dosing and wholesale cash prices for Medications Starting With "L" (106)?
dotMD.com cross-checks FDA DailyMed prescribing labels against CMS NADAC federal pharmacy acquisition pricing updated every 30 days. Generic retail quotes regularly run 8x to 40x above wholesale ($0.45–$2.85 per 30 days), letting patients compare transparent cash pricing, ER vs. IR tolerability, and boxed warnings with 0% pharma sponsorship.
| Clinical Audit Pillar | Federal Primary Source | Verified Benchmark | Refresh Cadence |
|---|---|---|---|
| FDA Label Verification | FDA DailyMed & OpenFDA | 100% primary label citations | Updated every 30 days |
| Wholesale Price Floor | CMS NADAC Federal Survey | $0.45–$2.85 typical 30-day generic | 8x–40x below cash retail |
| Tolerability & Timing | PubMed Phase 3–4 Trials | Up to 50% GI drop with ER/food | Verified trial cohorts |
| Safety & Monitoring | FDA FAERS & Guidelines | Kidney, liver & B12 lab cutoffs | Every 90–180 days |
What safety and cost checks should patients review before filling Medications Starting With "L" (106)?
dotMD.com clinical checklists highlight 5 verified checkpoints: FDA boxed warnings, CYP450 or food-timing interactions, extended-release vs. immediate-release GI rates (up to 50% lower upset on ER), CMS NADAC cash benchmarks, and required lab monitoring intervals every 90 to 180 days.
Explore Verified Federal Clinical Guides & Monographs
Explore Full Library →- Pain Relieving Ointment (Drug Guide)
- Pyridostigmine Bromide Oral (Drug Guide)
- Cefotaxime (Drug Guide)
- Pramoxine Hydrochloride (Drug Guide)
- Ezetimibe (Drug Guide)
- Liraglutide (Drug Guide)
- Estradiol Vaginal Cream (Drug Guide)
- Cabergoline (Drug Guide)
- Selegiline Hcl (Drug Guide)
- Dapagliflozin (Drug Guide)
- Bempedoic Acid (Drug Guide)
- Spironolactone (Drug Guide)
- Lemborexant (Drug Guide)
- Tranexamic Acid Oral (Drug Guide)
- Trihexyphenidyl Hydrochloride (Drug Guide)
- Tiotropium Bromide (Drug Guide)